Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78105
Title:
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.
Authors:
Sykes, Andrew J; Slevin, Nicholas J ( 0000-0002-3367-7013 ) ; MacDougall, Robert H; Ironside, Janet A D; Mais, Kathleen L
Abstract:
Capecitabine is preferentially converted to 5-fluorouracil within tumours, exploiting the higher levels of thymidine phosphorylase (TP) found in areas of poor perfusion and hypoxia. In addition radiation leads to up regulation of TP expression. To exploit these advantages of capecitabine as a synchronous chemoradiotherapy agent patients with advanced squamous cell carcinoma of the head and neck were recruited into a phase I non-randomised dose finding study. Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid. Radiotherapy using a beam directed technique was prescribed to 55 Gy in 20 fractions over 4 weeks. A total of 24 patients were treated. Dose-limiting toxicity (grade IV mucositis) was reached at a capecitabine dose of 550 mg/m(2) bid. Radiotherapy was completed without delay in all cases. There was no systemic drug related toxicity. Capecitabine offers the prospect of an orally administered drug for use synchronously with radiotherapy, which in doses up to 500 mg/m(2) bid is well tolerated.
Affiliation:
Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK.
Citation:
Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. 2004, 71 (1):81-4 Radiother Oncol
Journal:
Radiotherapy and Oncology
Issue Date:
Apr-2004
URI:
http://hdl.handle.net/10541/78105
DOI:
10.1016/j.radonc.2004.02.001
PubMed ID:
15066299
Type:
Article
Language:
en
ISSN:
0167-8140
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSykes, Andrew J-
dc.contributor.authorSlevin, Nicholas J-
dc.contributor.authorMacDougall, Robert H-
dc.contributor.authorIronside, Janet A D-
dc.contributor.authorMais, Kathleen L-
dc.date.accessioned2009-08-21T09:41:26Z-
dc.date.available2009-08-21T09:41:26Z-
dc.date.issued2004-04-
dc.identifier.citationResults of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. 2004, 71 (1):81-4 Radiother Oncolen
dc.identifier.issn0167-8140-
dc.identifier.pmid15066299-
dc.identifier.doi10.1016/j.radonc.2004.02.001-
dc.identifier.urihttp://hdl.handle.net/10541/78105-
dc.description.abstractCapecitabine is preferentially converted to 5-fluorouracil within tumours, exploiting the higher levels of thymidine phosphorylase (TP) found in areas of poor perfusion and hypoxia. In addition radiation leads to up regulation of TP expression. To exploit these advantages of capecitabine as a synchronous chemoradiotherapy agent patients with advanced squamous cell carcinoma of the head and neck were recruited into a phase I non-randomised dose finding study. Capecitabine was given twice daily, 7 days a week at a dose starting at 350 mg/m(2) bid. Radiotherapy using a beam directed technique was prescribed to 55 Gy in 20 fractions over 4 weeks. A total of 24 patients were treated. Dose-limiting toxicity (grade IV mucositis) was reached at a capecitabine dose of 550 mg/m(2) bid. Radiotherapy was completed without delay in all cases. There was no systemic drug related toxicity. Capecitabine offers the prospect of an orally administered drug for use synchronously with radiotherapy, which in doses up to 500 mg/m(2) bid is well tolerated.en
dc.language.isoenen
dc.subjectOtorhinolaryngologic Canceren
dc.subject.meshAdministration, Oral-
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshDeoxycytidine-
dc.subject.meshDrug Evaluation-
dc.subject.meshFluorouracil-
dc.subject.meshHumans-
dc.subject.meshMucous Membrane-
dc.subject.meshOtorhinolaryngologic Neoplasms-
dc.subject.meshProdrugs-
dc.subject.meshRadiation Injuries-
dc.subject.meshRadiation-Sensitizing Agents-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshStomatitis-
dc.titleResults of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Wilmslow Road, Manchester M20 4BX, UK.en
dc.identifier.journalRadiotherapy and Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.